期刊
JOURNAL OF THORACIC ONCOLOGY
卷 13, 期 1, 页码 97-105出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jtho.2017.10.030
关键词
Non-small cell lung cancer; Nivolumab; Peripheral blood biomarker; Prognostic factor; Predictive factor
资金
- Kyowa Hakko Kirin Co.
- MSD K.K.
- Ono Pharmaceutical Co.
- Yakult Honsha Co.
- Merck Serono
- Pfizer Japan
- Chugai Pharmaceutical Co
- Eli Lilly Japan K.K.
- GlaxoSmithKline K.K.
- Japan Clinical Research Operations Co
- Eisai
- EPS Associates
- AstraZeneca K.K.
- Daiichi Sankyo Co.
- Astellas Pharma
- Boehringer Ingelheim Japan
- Kyowa Hakko Kirin Co
- AbbVie
- AC MEDICAL
- PPD-SNBL
- Quintiles Transnational Japan K.K.
- Takeda Pharmaceutical Co.
- Chugai Pharmaceutical Co.
- Novartis Pharma K.K.
- Taiho Pharmaceutical Co.
- Otsuka Pharmaceutical Co.
- PAREXEL International
- Bristol-Myers Squibb
Objective: The aim of this study was to identify baseline peripheral blood biomarkers associated with clinical outcome in patients with NSCLC treated with nivolumab. Methods: Univariable and multivariable analyses were performed retrospectively for 134 patients with advanced or recurrent NSCLC treated with nivolumab to evaluate the relationship between survival and peripheral blood parameters measured before treatment initiation, including absblute neutrophil count (ANC), absolute lymphocyte count (ALC), absolute monocyte count, and absolute eosinophil count (AEC), as well as serum C-reactive protein and lactate dehydrogenase levels. Progression-free survival, overall survival, and response rate were determined. Results: Among the variables selected by univariable analysis, a low ANC, high ALC, and high AEC were significantly and independently associated with both better progression-free survival (p = 0.001, p = 0.04, and p = 0.02, respectively) and better overall survival (p = 0.03, p = 0.03, and p = 0.003, respectively) in multivariable analysis. Categorization of patients according to the number of favorable factors revealed that those with only one factor had a significantly worse outcome than those with two or three factors. A similar trend was apparent for patients with a programmed death 1 ligand tumor proportion score less than 50%, whereas all patients with a score of 50% or higher had at least two favorable factors. Conclusions: A baseline signature of a low ANC, high ALC, and high AEC was associated with a better outcome of nivolumab treatment, with the number of favorable factors identifying subgroups of patients differing in survival and response rate. (C) 2017 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据